2 posts Page 1 of 1

The study revealed a 68 percent improvement over the placebo in slowing the rate of whole brain atrophy in patients with secondary progressive MS. For the sake of comparison, a clinical trial involving the recent FDA-approved pharmaceutical Ocrevus showed an 18 percent improvement over a placebo in slowing the rate of whole brain atrophy for patients with primary progressive forms of the disease.

Lipoic Acid has been around a long time. Some years ago it was shown to have efficacy in treating EAE, the mouse model of MS. It's good to see that it is still being studied. Hopefully this sudy will be expanded. It's difficult to see the path to making any big financial gains for a supplement company but the data presented so far looks really encouraging. If you do the math, the retail cost of Ocrevus comes in at around $65,000 per year. I know, that's crazy ...

https://seekingalpha.com/article/405893 ... disruption

So how do you convince the world of doctors, hospital, nurses, patients, etc. etc. that a supplement costing $12 a bottle can be competitive. Herein lies the huge problem we face in finding better treatments for the more challenging forms of MS.
Thank you for this article. Because of it I added Lipoic acid (1200 mg) to my daily supplements. My neurologist is proposing Ocrelizumab and of course I take that serious too. But there's no reason not to take both.
2 posts Page 1 of 1

Who is online

Users browsing this forum: No registered users and 4 guests